Jaunt

Tag #curesjia

NextGen 2024: Weaning meds when disease is controlled Session Part 2

NextGen 2024: Weaning meds when disease is controlled Session Part 1

NextGen 2024: Genetics in SJIA Session Part 3

NextGen 2024: Genetics in SJIA Session Part 2

NextGen 2024: Genetics in SJIA Session Part 1

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 2

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 1

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 5

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 4

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 3

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 2

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 1

$NextGen 2024: Refractory SJIA & MAS Session Part 8$

$NextGen 2024: Refractory SJIA & MAS Session Part 7$

$NextGen 2024: Refractory SJIA & MAS Session Part 6$

$NextGen 2024: Refractory SJIA & MAS Session Part 5$

$NextGen 2024: Refractory SJIA & MAS Session Part 4$

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 2

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 1

$NextGen 2024: Refractory SJIA & MAS Session Part 3$

$NextGen 2024: Refractory SJIA & MAS Session Part 2$

$NextGen 2024: Refractory SJIA & MAS Session Part 1$

IL-18 testing in the diagnosis and management of Still’s disease:
Game-changer or Red Herring?

Clinical significance of serum IL-18 levels
for the diagnosis and monitoring of disease activity

BMT in SJIA patients

This website uses cookies to improve your experience. By using this site, you consent to the use of cookies.